[6-K] KAMADA LTD Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Kamada Ltd. furnished a Form 6-K and attached an exhibit announcing a clinical milestone for CYTOGAM. The filing states it is incorporated by reference into the company’s Form S-8 registration statements.

Exhibit 99.1 is titled “Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation.” This indicates the study is led by independent investigators and marks the start of patient enrollment focused on CMV prevention in kidney transplant recipients. The report was signed by Nir Livneh, Vice President General Counsel and Corporate Secretary.

Insights

Biotech and regulatory analyst

Informational 6-K; early clinical activity, limited near-term impact.

Kamada furnished a Form 6-K that includes an exhibit noting first-patient enrollment in an investigator-initiated trial of CYTOGAM for CMV prevention in kidney transplantation. Investigator-initiated trials are designed and run by external investigators, signaling clinical interest without committing the company to disclosed new spend in this excerpt.

The action represents an early clinical step, not a regulatory approval or commercial event. Proceeds, timelines, or endpoints are not detailed in the excerpt, so the immediate financial impact cannot be inferred. Subsequent filings may provide design details or outcomes.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the Month of November 2025

Commission File Number 001-35948

Kamada Ltd.

(Translation of registrant’s name into English)

2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267 and 333-265866.

The following exhibit is attached:

99.1 Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation

1 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 4, 2025	KAMADA LTD.
	By:	/s/ Nir Livneh
		Nir Livneh Vice President General Counsel and Corporate Secretary

2 

EXHIBIT INDEX

EXHIBIT NO.		DESCRIPTION
99.1		Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation

3 

FAQ

What did Kamada (KMDA) file?

Kamada furnished a Form 6-K that is incorporated by reference into certain Form S-8 registration statements.

What is highlighted in Exhibit 99.1 of Kamada’s 6-K?

Exhibit 99.1 announces the first patient enrolled in an investigator-initiated clinical trial of CYTOGAM to prevent cytomegalovirus in kidney transplantation.

Who signed Kamada’s 6-K and in what capacity?

It was signed by Nir Livneh, Vice President General Counsel and Corporate Secretary.

When was the report signed?

The report was signed on November 4, 2025.

Is the CYTOGAM study company-sponsored?

The exhibit describes an investigator-initiated clinical trial.